Cytomegalovirus infection/disease after hematopoietic stem cell transplantation

Area of Science:

• Hematology
• Infectious Diseases
• Immunology

Background:

• Cytomegalovirus (CMV) disease historically led to significant mortality post-allogeneic hematopoietic stem cell transplantation (HSCT).
• Prophylactic and preemptive therapies have reduced CMV disease incidence, but breakthrough infections, especially gastrointestinal, persist as major complications.
• Ganciclovir's myelotoxicity and impact on immune reconstitution contribute to late CMV disease, highlighting the need for alternatives.

Purpose of the Study:

• To review current knowledge and recent advancements in managing CMV infection and disease following allogeneic HSCT.
• To discuss alternative antiviral agents and their clinical utility.
• To explore the potential of individualized approaches based on CMV-specific T cell monitoring.

Main Methods:

• Literature review of recent progress in understanding CMV infection and disease after HSCT.
• Analysis of current therapeutic strategies, including prophylactic, preemptive, and alternative antiviral treatments.
• Discussion of emerging technologies for assessing CMV-specific immune reconstitution.

Main Results:

• Breakthrough CMV gastrointestinal disease remains a significant challenge despite current therapies.
• Alternative antivirals like foscarnet and valganciclovir offer different toxicity profiles and clinical advantages.
• Technological advancements allow for visualization and isolation of CMV-specific T cells, enabling personalized immune monitoring.

Conclusions:

• While CMV disease incidence has decreased, breakthrough infections and late-onset disease post-HSCT require ongoing attention.
• Alternative antiviral agents provide valuable options for managing CMV in HSCT recipients.
• Personalized monitoring of immune reconstitution against CMV holds promise for future treatment strategies.